Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Phase I trial of new vaccine is underway
May 19th, 2005
Generex Biotechnology Corporation (GNBT) announced on April 28, 2005, that the first patients had received a novel therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express, as part of the company's Phase I Trial. The Trial will include between 16 and 24 patients. The compound, AE37, is designed to stimulate an immune response against the tumor-causing gene HER-2/neu, which occurs in a significant percentage of patients with breast cancer as well as other cancers. A robust immune response against HER-2/neu has the potential to destroy tumor cells even at sites in the body distant from the primary tumor. There...
Source: Women's Health Weekly (2005-05-19)
|
